Follow
Juan Luis Callejas-Valera
Juan Luis Callejas-Valera
Primity Bio
Verified email at primitybio.com
Title
Cited by
Cited by
Year
Transcriptional signature primes human oral mucosa for rapid wound healing
R Iglesias-Bartolome, A Uchiyama, AA Molinolo, L Abusleme, SR Brooks, ...
Science translational medicine 10 (451), eaap8798, 2018
1832018
Assembly and activation of the Hippo signalome by FAT1 tumor suppressor
D Martin, MS Degese, L Vitale-Cross, R Iglesias-Bartolome, JLC Valera, ...
Nature communications 9 (1), 2372, 2018
1372018
P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance
MA De la Cruz-Morcillo, MLL Valero, JL Callejas-Valera, ...
Oncogene 31 (9), 1073-1085, 2012
1352012
Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4
Z Wang, VH Wu, MM Allevato, M Gilardi, Y He, J Luis Callejas-Valera, ...
Nature communications 10 (1), 5546, 2019
1182019
Safety and efficacy of pembrolizumab with chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a phase IB study
SF Powell, KA Gold, MM Gitau, CJ Sumey, MM Lohr, SC McGraw, ...
Journal of Clinical Oncology 38 (21), 2427, 2020
952020
Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas
M Gilardi, Z Wang, M Proietto, A Chillà, JL Calleja-Valera, Y Goto, ...
Molecular cancer therapeutics 19 (9), 1784-1796, 2020
872020
Inhibition of mTOR signaling and clinical activity of rapamycin in head and neck cancer in a window of opportunity trial
TA Day, K Shirai, PE O'Brien, MG Matheus, K Godwin, AJ Sood, ...
Clinical Cancer Research 25 (4), 1156-1164, 2019
812019
mTOR co-targeting strategies for head and neck cancer therapy
Z Wang, JC Valera, X Zhao, Q Chen, J Silvio Gutkind
Cancer and Metastasis Reviews 36, 491-502, 2017
692017
HPV E2, E4, E5 drive alternative carcinogenic pathways in HPV positive cancers
S Ren, DA Gaykalova, T Guo, AV Favorov, EJ Fertig, P Tamayo, ...
Oncogene 39 (40), 6327-6339, 2020
652020
ERK2, but Not ERK1, Mediates Acquired and “De novo” Resistance to Imatinib Mesylate: Implication for CML Therapy
CI Aceves-Luquero, A Agarwal, JL Callejas-Valera, L Arias-González, ...
PloS one 4 (7), e6124, 2009
542009
Balance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin in NSCLC
EM Galan-Moya, MA de la Cruz-Morcillo, ML Valero, JL Callejas-Valera, ...
PloS one 6 (12), e28406, 2011
522011
ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma
L Arias-González, I Moreno-Gimeno, AR del Campo, SO Leticia, ...
Neoplasia 15 (6), 649-IN17, 2013
502013
mTOR inhibition prevents rapid-onset of carcinogen-induced malignancies in a novel inducible HPV-16 E6/E7 mouse model
JL Callejas-Valera, R Iglesias-Bartolome, P Amornphimoltham, ...
Carcinogenesis 37 (10), 1014-1025, 2016
412016
c‐Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin‐based therapy
EM Galan‐Moya, J Hernandez‐Losa, CI Aceves Luquero, ...
International journal of cancer 122 (2), 289-297, 2008
402008
Control of the epithelial stem cell epigenome: the shaping of epithelial stem cell identity
R Iglesias-Bartolome, JL Callejas-Valera, JS Gutkind
Current opinion in cell biology 25 (2), 162-169, 2013
372013
E1a gene expression blocks the ERK1/2 signaling pathway by promoting nuclear localization and MKP up-regulation: implication in vH-Ras-induced senescence
JL Callejas-Valera, J Guinea-Viniegra, C Ramírez-Castillejo, JA Recio, ...
Journal of biological chemistry 283 (19), 13450-13458, 2008
252008
A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers
K Yamaguchi, R Iglesias-Bartolomé, Z Wang, JL Callejas-Valera, ...
Oncotarget 7 (10), 10696, 2016
182016
β2-Adrenergic receptor modulates mitochondrial metabolism and disease progression in recurrent/metastatic HPV(+) HNSCC
CT Lucido, JL Callejas-Valera, PL Colbert, DW Vermeer, WK Miskimins, ...
Oncogenesis 7 (10), 81, 2018
152018
E1a is an exogenous in vivo tumour suppressor
FJ Cimas, JL Callejas-Valera, DC García-Olmo, J Hernández-Losa, ...
Cancer Letters 399, 74-81, 2017
152017
MKP1 mediates chemosensitizer effects of E1a in response to cisplatin in non-small cell lung carcinoma cells
FJ Cimas, JL Callejas-Valera, R Pascual-Serra, J García-Cano, ...
Oncotarget 6 (42), 44095, 2015
132015
The system can't perform the operation now. Try again later.
Articles 1–20